Natural Polyphenols in Cancer Chemoresistance

Nutrition and Cancer

Volumn 68, Issue 6, 2016, Pages 879-891

  Hussain, Saad A ^a   Sulaiman, Amal A ^a   Balch, Curt ^b   Chauhan, Harsh ^c   Alhadidi, Qasim M ^d   Tiwari, Amit K ^b  

^a UNIVERSITY OF BAGHDAD   (Iraq)

^b UNIVERSITY OF TOLEDO   (United States)

^c CREIGHTON UNIVERSITY   (United States)

^d MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLAVONOID; MULTIDRUG RESISTANCE PROTEIN; NATURAL PRODUCT; POLYPHENOL DERIVATIVE; BENZENE DERIVATIVE; POLYPHENOL; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CELL METABOLISM; DIET; DNA REPAIR; DRUG MECHANISM; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEMBRANE TRANSPORT; MULTIDRUG RESISTANCE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PHENOTYPE; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; DIET THERAPY; DIETARY SUPPLEMENT; DRUG RESISTANCE; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASM; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BENZENE DERIVATIVES; BIOLOGICAL TRANSPORT; COMBINED MODALITY THERAPY; DIETARY SUPPLEMENTS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLAVONOIDS; HUMANS; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS; POLYPHENOLS;

EID: 84978796186     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2016.1192201     Document Type: Review

References (147)

1. A.Jemal, F.Bray, M.M.Center, J.Ferlay, and E.Ward, et al.: Global cancer statistics. CA Cancer J Clin 61, 69–90, 2011.
2. M.H.Teiten, M.Dicato, and M.Diederich: Hybrid curcumin compounds: a new strategy for cancer treatment. Molecules 19, 20839–20863, 2014.
3. Y.A.Luqmani: Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 14 Suppl 1, 35–48, 2005.
4. S.M.Simon and M.Schindler: Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 91, 3497–3504, 1994.
5. L.H.Hurley: DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer 2, 188–200, 2002.
6. J.H.Goldie and A.J.Coldman: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63, 1727–1733, 1979.
7. J.C.van der Mijn, J.W.Mier, H.J.Broxterman, and H.M.Verheul: Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms. Drug Resist Updat 17, 77–88, 2014.
8. D.B.Longley and P.G.Johnston: Molecular mechanisms of drug resistance. J Pathol 205, 275–292, 2005.
9. M.M.Gottesman and I.Pastan: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62, 385–427, 1993.
10. B.C.Baguley: Multidrug resistance in cancer. Methods Mol Biol 596, 1–14, 2010.
11. H.Lage: An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 65, 3145–3167, 2008.
12. B.C.Shaffer, J.P.Gillet, C.Patel, M.R.Baer, S.E.Bates, et al.: Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat 15, 62–69, 2012.
13. E.Yague, A.Arance, L.Kubitza, M.O'Hare, P.Jat, et al.: Ability to acquire drug resistance arises early during the tumorigenesis process. Cancer Res 67, 1130–1137, 2007.
14. S.Raguz and E.Yague: Resistance to chemotherapy: new treatments and novel insights into an old problem. Br J Cancer 99, 387–391, 2008.
15. M.M.Gottesman: Mechanisms of cancer drug resistance. Annu Rev Med 53, 615–627, 2002.
16. D.Fukumura and R.K.Jain: Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 101, 937–949, 2007.
17. J.Mattern and M.Volm: Role of oxygenation and vascularization in drug resistance. Cytotechnology 27, 249–256, 1998.
18. O.Tredan, C.M.Galmarini, K.Patel, and I.F.Tannock: Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99, 1441–1454, 2007.
19. W.Bardenheuer, K.Lehmberg, I.Rattmann, A.Brueckner, A.Schneider, et al.: Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells. Leukemia 19, 2281–2288, 2005.
20. D.M.Townsend and K.D.Tew: The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22, 7369–7375, 2003.
21. P.Borst, R.Evers, M.Kool, and J.Wijnholds: A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92, 1295–1302, 2000.
22. Z.Wang, Y.Xu, X.Meng, F.Watari, H.Liu, et al.: Suppression of c-Myc is involved in multi-walled carbon nanotubes' down-regulation of ATP-binding cassette transporters in human colon adenocarcinoma cells. Toxicol Appl Pharmacol 282, 42–51, 2014.
23. C.Kast and P.Gros: Topology mapping of the amino-terminal half of multidrug resistance-associated protein by epitope insertion and immunofluorescence. J Biol Chem 272, 26479–26487, 1997.
24. C.International Transporter, K.M.Giacomini, S.M.Huang, D.J.Tweedie, L.Z.Benet, et al.: Membrane transporters in drug development. Nat Rev Drug Discov 9, 215–236, 2010.
25. M.Dean, A.Rzhetsky, and R.Allikmets: The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11, 1156–1166, 2001.
26. M.M.Gottesman, I.Pastan, and S.V.Ambudkar: P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 6, 610–617, 1996.
27. M.M.Gottesman, T.Fojo, and S.E.Bates: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2, 48–58, 2002.
28. J.Y.Yhee, S.Song, S.J.Lee, S.Park, K.Kim, et al.: Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance. J Control Release 198C, 1–9, 2014.
29. E.M.Leslie, R.G.Deeley, and S.P.Cole: Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204, 216–237, 2005.
30. K.Nooter, A.M.Westerman, M.J.Flens, G.J.Zaman, R.J.Scheper, et al.: Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 1, 1301–1310, 1995.
31. J.Sun, Z.G.He, G.Cheng, S.J.Wang, X.H.Hao, et al.: Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med Sci Monit 10, RA5–14, 2004.
32. H.E.Bryant, N.Schultz, H.D.Thomas, K.M.Parker, D.Flower, et al.: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917, 2005.
33. H.Farmer, N.McCabe, C.J.Lord, A.N.Tutt, D.A.Johnson, et al.: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921, 2005.
34. J.L.Riffell, C.J.Lord, and A.Ashworth: Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat Rev Drug Discov 11, 923–936, 2012.
35. A.Chiarugi: A snapshot of chemoresistance to PARP inhibitors. Trends Pharmacol Sci 33, 42–48, 2012.
36. A.Montoni, M.Robu, E.Pouliot, and G.M.Shah: Resistance to PARP-Inhibitors in Cancer Therapy. Front Pharmacol 4, 18, 2013.
37. Y.Wang, Y.A.Suh, M.Y.Fuller, J.G.Jackson, S.Xiong, et al.: Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest 121, 893–904, 2011.
38. L.Chen, Y.Zhao, G.C.Halliday, P.Berry, R.F.Rousseau, et al.: Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma. Br J Cancer 111, 716–725, 2014.
39. J.B.Almond and G.M.Cohen: The proteasome: a novel target for cancer chemotherapy. Leukemia 16, 433–443, 2002.
40. Z.J.Yang, C.E.Chee, S.Huang, and F.A.Sinicrope: The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther 10, 1533–1541, 2011.
41. X.L.Guo, D.Li, F.Hu, J.R.Song, S.S.Zhang, et al.: Targeting autophagy potentiates chemotherapy-induced apoptosis and proliferation inhibition in hepatocarcinoma cells. Cancer Lett 320, 171–179, 2012.
42. S.Zhou, L.Zhao, M.Kuang, B.Zhang, Z.Liang, et al.: Autophagy in tumorigenesis and cancer therapy: Dr. Jekyll or Mr. Hyde?. Cancer Lett 323, 115–127, 2012.
43. G.M.Ajabnoor, T.Crook, and H.M.Coley: Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells. Cell Death Dis 3, e260, 2012.
44. S.A.Rushworth and D.J.Macewan: The role of nrf2 and cytoprotection in regulating chemotherapy resistance of human leukemia cells. Cancers (Basel) 3, 1605–1621, 2011.
45. I.B.Weinstein and A.Joe: Oncogene addiction. Cancer Res 68, 3077–3080; discussion 3080, 2008.
46. S.V.Sharma and J.Settleman: Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 21, 3214–3231, 2007.
47. D.Gioeli, W.Wunderlich, J.Sebolt-Leopold, S.Bekiranov, J.D.Wulfkuhle, et al.: Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer. Mol Cancer Ther 10, 1581–1590, 2011.
48. E.Jabbour, H.Kantarjian, D.Jones, M.Breeden, G.Garcia-Manero, et al.: Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112, 53–55, 2008.
49. D.B.Costa, B.Halmos, A.Kumar, S.T.Schumer, M.S.Huberman, et al.: BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 4, 1669–1679; discussion 1680, 2007.
50. M.Greaves: Darwinian medicine: a case for cancer. Nat Rev Cancer 7, 213–221, 2007.
51. D.A.Yardley: Drug resistance and the role of combination chemotherapy in improving patient outcomes. Int J Breast Cancer 2013, 137414, 2013.
52. A.M.Weber and A.J.Ryan: ATM and ATR as therapeutic targets in cancer. Pharmacol Ther 149, 124–138, 2015.
53. M.F.Ullah: Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. Asian Pac J Cancer Prev 9, 1–6, 2008.
54. T.P.Miller, T.M.Grogan, W.S.Dalton, C.M.Spier, R.J.Scheper, et al.: P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9, 17–24, 1991.
55. F.Leonessa, J.H.Kim, A.Ghiorghis, R.J.Kulawiec, C.Hammer, et al.: C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump. J Med Chem 45, 390–398, 2002.
56. N.Bluthgen, J.P.Sumpter, A.Odermatt, and K.Fent: Effects of low concentrations of the antiprogestin mifepristone (RU486) in adults and embryos of zebrafish (Danio rerio): 2. Gene expression analysis and in vitro activity. Aquat Toxicol 144–145, 96–104, 2013.
57. Z.Mao, J.Zhou, J.Luan, W.Sheng, X.Shen, et al.: Tamoxifen reduces P-gp-mediated multidrug resistance via inhibiting the PI3K/Akt signaling pathway in ER-negative human gastric cancer cells. Biomed Pharmacother 68, 179–183, 2014.
58. K.M.Barnes, B.Dickstein, G.B.Cutler, Jr., T.Fojo, and S.E.Bates: Steroid treatment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Biochemistry 35, 4820–4827, 1996.
59. I.Cohen, J.Bernheim, R.Azaria, R.Tepper, R.Sharony, et al.: Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients. Gynecol Oncol 75, 136–141, 1999.
60. M.Shiota, A.Yokomizo, A.Takeuchi, K.Imada, E.Kashiwagi, et al.: Inhibition of protein kinase C/Twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer. Clin Cancer Res 20, 951–961, 2014.
61. D.Granato, A.R.Karnopp, and S.M.van Ruth: Characterization and comparison of phenolic composition, antioxidant capacity and instrumental taste profile of juices from different botanical origins. J Sci Food Agric, 2014.
62. M.Shike, A.S.Doane, L.Russo, R.Cabal, J.Reis-Filo, et al.: The effects of soy supplementation on gene expression in breast cancer: a randomized placebo-controlled study. J Natl Cancer Inst 106, 2014.
63. M.T.Sheu, Y.B.Liou, Y.H.Kao, Y.K.Lin, and H.O.Ho: A quantitative structure-activity relationship for the modulation effects of flavonoids on p-glycoprotein-mediated transport. Chem Pharm Bull 58, 1187–1194, 2010.
64. J.A.Ross and C.M.Kasum: Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr 22, 19–34, 2002.
65. A.Kale, S.Gawande, and S.Kotwal: Cancer phytotherapeutics: role for flavonoids at the cellular level. Phytother Res 22, 567–577, 2008.
66. T.Bansal, M.Jaggi, R.K.Khar, and S.Talegaonkar: Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 12, 46–78, 2009.
67. M.E.Morris and S.Zhang: Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci 78, 2116–2130, 2006.
68. M.Saeed, O.Kadioglu, H.Khalid, Y.Sugimoto, and T.Efferth: Activity of the dietary flavonoid, apigenin, against multidrug-resistant tumor cells as determined by pharmacogenomics and molecular docking. J Nutr Biochem 26, 44–56, 2015.
69. K.F.Chan, I.L.Wong, J.W.Kan, C.S.Yan, L.M.Chow, et al.: Amine linked flavonoid dimers as modulators for P-glycoprotein-based multidrug resistance: structure-activity relationship and mechanism of modulation. J Med Chem 55, 1999–2014, 2012.
70. V.H.Tran, D.Marks, R.K.Duke, M.Bebawy, C.C.Duke, et al.: Modulation of P-glycoprotein-mediated anticancer drug accumulation, cytotoxicity, and ATPase activity by flavonoid interactions. Nutr Cancer 63, 435–443, 2011.
71. A.I.Alvarez, R.Real, M.Perez, G.Mendoza, J.G.Prieto, et al.: Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response. J Pharm Sci 99, 598–617, 2010.
72. R.M.Laberge, R.Ambadipudi, and E.Georges: P-glycoprotein mediates the collateral sensitivity of multidrug resistant cells to steroid hormones. Biochem Biophys Res Commun 447, 574–579, 2014.
73. T.Thangasamy, S.Sittadjody, G.C.Mitchell, E.E.Mendoza, V.M.Radhakrishnan, et al.: Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73. BMC Cancer 10, 282, 2010.
74. G.Scambia, F.O.Ranelletti, P.B.Panici, R.De Vincenzo, G.Bonanno, et al.: Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 34, 459–464, 1994.
75. A.B.Ke, S.Eyal, F.S.Chung, J.M.Link, D.A.Mankoff, et al.: Modeling cyclosporine A inhibition of the distribution of a P-glycoprotein PET ligand, 11C-verapamil, into the maternal brain and fetal liver of the pregnant nonhuman primate: impact of tissue blood flow and site of inhibition. J Nucl Med 54, 437–446, 2013.
76. I.Murtaza, V.M.Adhami, B.B.Hafeez, M.Saleem, and H.Mukhtar: Fisetin, a natural flavonoid, targets chemoresistant human pancreatic cancer AsPC-1 cells through DR3-mediated inhibition of NF-kappaB. Int J Cancer 125, 2465–2473, 2009.
77. S.Kitagawa, T.Nabekura, T.Takahashi, Y.Nakamura, H.Sakamoto, et al.: Structure-activity relationships of the inhibitory effects of flavonoids on P-glycoprotein-mediated transport in KB-C2 cells. Biol Pharm Bull 28, 2274–2278, 2005.
78. P.Limtrakul, O.Khantamat, and K.Pintha: Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J Chemother 17, 86–95, 2005.
79. R.Badhan and J.Penny: In silico modelling of the interaction of flavonoids with human P-glycoprotein nucleotide-binding domain. Eur J Med Chem 41, 285–295, 2006.
80. P.J.Lee, I.Shin, S.Y.Seo, H.Kim, and H.P.Kim: Upregulation of both heme oxygenase-1 and ATPase inhibitory factor 1 renders tumoricidal activity by synthetic flavonoids via depleting cellular ATP. Bioorg Med Chem Lett 24, 4845–4849, 2014.
81. E.M.Leslie, R.G.Deeley, and S.P.Cole: Bioflavonoid stimulation of glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). Drug Metab Dispos 31, 11–15, 2003.
82. S.H.Kim, G.S.Yeo, Y.S.Lim, C.D.Kang, C.M.Kim, et al.: Suppression of multidrug resistance via inhibition of heat shock factor by quercetin in MDR cells. Exp Mol Med 30, 87–92, 1998.
83. Y.Sadzuka, T.Sugiyama, and T.Sonobe: Efficacies of tea components on doxorubicin induced antitumor activity and reversal of multidrug resistance. Toxicol Lett 114, 155–162, 2000.
84. C.H.Versantvoort, G.J.Schuurhuis, H.M.Pinedo, C.A.Eekman, C.M.Kuiper, et al.: Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. Br J Cancer 68, 939–946, 1993.
85. A.F.Castro and G.A.Altenberg: Inhibition of drug transport by genistein in multidrug-resistant cells expressing P-glycoprotein. Biochem Pharmacol 53, 89–93, 1997.
86. J.H.Hooijberg, H.J.Broxterman, M.Heijn, D.L.Fles, J.Lankelma, et al.: Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein. FEBS Lett 413, 344–348, 1997.
87. M.Wiese and I.K.Pajeva: Structure-activity relationships of multidrug resistance reversers. Curr Med Chem 8, 685–713, 2001.
88. K.Katayama, K.Masuyama, S.Yoshioka, H.Hasegawa, J.Mitsuhashi, et al.: Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship. Cancer Chemother Pharmacol 60, 789–797, 2007.
89. J.S.Choi, Y.J.Piao, and K.W.Kang: Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin. Arch Pharm Res 34, 607–613, 2011.
90. S.Borska, M.Chmielewska, T.Wysocka, M.Drag-Zalesinska, M.Zabel, et al.: In vitro effect of quercetin on human gastric carcinoma: targeting cancer cells death and MDR. Food Chem Toxicol 50, 3375–3383, 2012.
91. J.Yuan, I.L.Wong, T.Jiang, S.W.Wang, T.Liu, et al.: Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumour cells. Eur J Med Chem 54, 413–422, 2012.
92. R.W.Robey, K.K.To, O.Polgar, M.Dohse, P.Fetsch, et al.: ABCG2: a perspective. Adv Drug Deliv Rev 61, 3–13, 2009.
93. Y.Sugimoto, S.Tsukahara, E.Ishikawa, and J.Mitsuhashi: Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics. Cancer Sci 96, 457–465, 2005.
94. K.Noguchi, K.Katayama, J.Mitsuhashi, and Y.Sugimoto: Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev 61, 26–33, 2009.
95. D.O.Kennedy: Polyphenols and the human brain: plant “secondary metabolite” ecologic roles and endogenous signaling functions drive benefits. Adv Nutr 5, 515–533, 2014.
96. Y.Imai, S.Tsukahara, S.Asada, and Y.Sugimoto: Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res 64, 4346–4352, 2004.
97. Y.W.Li, Y.Zhang, L.Zhang, X.Li, J.B.Yu, et al.: Protective effect of tea polyphenols on renal ischemia/reperfusion injury via suppressing the activation of TLR4/NF-kappaB p65 signal pathway. Gene 542, 46–51, 2014.
98. T.Maraldi, D.Vauzour, and C.Angeloni: Dietary polyphenols and their effects on cell biochemistry and pathophysiology 2013. Oxid Med Cell Longev 2014, 576363, 2014.
99. J.N.Lin, V.C.Lin, K.M.Rau, P.C.Shieh, D.H.Kuo, et al.: Resveratrol modulates tumor cell proliferation and protein translation via SIRT1-dependent AMPK activation. J Agric Food Chem 58, 1584–1592, 2010.
100. R.P.Singh, G.U.Mallikarjuna, G.Sharma, S.Dhanalakshmi, A.K.Tyagi, et al.: Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. Clin Cancer Res 10, 8641–8647, 2004.
101. A.Tyagi, C.Agarwal, L.D.Dwyer-Nield, R.P.Singh, A.M.Malkinson, et al.: Silibinin modulates TNF-alpha and IFN-gamma mediated signaling to regulate COX2 and iNOS expression in tumorigenic mouse lung epithelial LM2 cells. Mol Carcinog 51, 832–842, 2012.
102. J.H.Kim, S.C.Gupta, B.Park, V.R.Yadav, and B.B.Aggarwal: Turmeric (Curcuma longa) inhibits inflammatory nuclear factor (NF)-kappaB and NF-kappaB-regulated gene products and induces death receptors leading to suppressed proliferation, induced chemosensitization, and suppressed osteoclastogenesis. Mol Nutr Food Res 56, 454–465, 2012.
103. T.Dorai and B.B.Aggarwal: Role of chemopreventive agents in cancer therapy. Cancer Lett 215, 129–140, 2004.
104. S.Fulda and K.M.Debatin: Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 64, 337–346, 2004.
105. Y.Tang, D.Y.Zhao, S.Elliott, W.Zhao, T.J.Curiel, et al.: Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression. Int J Oncol 31, 705–711, 2007.
106. D.Sadava and S.E.Kane: Silibinin reverses drug resistance in human small-cell lung carcinoma cells. Cancer Lett 339, 102–106, 2013.
107. A.K.Tyagi, C.Agarwal, D.C.Chan, and R.Agarwal: Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Rep 11, 493–499, 2004.
108. L.Zhou, P.Liu, B.Chen, Y.Wang, X.Wang, et al.: Silibinin restores paclitaxel sensitivity to paclitaxel-resistant human ovarian carcinoma cells. Anticancer Res 28, 1119–1127, 2008.
109. S.Dhanalakshmi, P.Agarwal, L.M.Glode, and R.Agarwal: Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and apoptotic death. Int J Cancer 106, 699–705, 2003.
110. S.A.Hussain and B.H.Marouf: Silibinin improves the cytotoxicity of methotrexate in chemo resistant human rhabdomyosarcoma cell lines. Saudi Med J 34, 1145–1150, 2013.
111. C.Bonneau, R.Rouzier, C.Geyl, A.Cortez, M.Castela, et al.: Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma. Gynecol Oncol, 2014.
112. J.J.Lu, Y.J.Cai, and J.Ding: The short-time treatment with curcumin sufficiently decreases cell viability, induces apoptosis and copper enhances these effects in multidrug-resistant K562/A02 cells. Mol Cell Biochem 360, 253–260, 2012.
113. T.Haraguchi, T.Kayashima, Y.Okazaki, J.Inoue, S.Mineo, et al.: Cecal succinate elevated by some dietary polyphenols may inhibit colon cancer cell proliferation and angiogenesis. J Agric Food Chem 62, 5589–5594, 2014.
114. A.Walter, N.Etienne-Selloum, M.Sarr, M.O.Kane, A.Beretz, et al.: Angiotensin II induces the vascular expression of VEGF and MMP-2 in vivo: preventive effect of red wine polyphenols. J Vasc Res 45, 386–394, 2008.
115. P.Fresco, F.Borges, C.Diniz, and M.P.Marques: New insights on the anticancer properties of dietary polyphenols. Med Res Rev 26, 747–766, 2006.
116. B.B.Aggarwal and S.Shishodia: Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71, 1397–1421, 2006.
117. E.M.Brown, C.I.Gill, G.J.McDougall, and D.Stewart: Mechanisms underlying the anti-proliferative effects of berry components in in vitro models of colon cancer. Curr Pharm Biotechnol 13, 200–209, 2012.
118. D.R.Woode, H.S.Aiyer, N.Sie, A.L.Zwart, L.Li, et al.: Effect of berry extracts and bioactive compounds on fulvestrant (ICI 182,780) sensitive and resistant cell lines. Int J Breast Cancer 2012, 147828, 2012.
119. D.Hanahan and R.A.Weinberg: Hallmarks of cancer: the next generation. Cell 144, 646–674, 2011.
120. R.J.DeBerardinis: Is cancer a disease of abnormal cellular metabolism? New angles on an old idea. Genet Med 10, 767–777, 2008.
121. D.Daye and K.E.Wellen: Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. Semin Cell Dev Biol 23, 362–369, 2012.
122. R.J.DeBerardinis, J.J.Lum, G.Hatzivassiliou, and C.B.Thompson: The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7, 11–20, 2008.
123. C.Yin, S.Qie, and N.Sang: Carbon source metabolism and its regulation in cancer cells. Crit Rev Eukaryot Gene Exp 22, 17–35, 2012.
124. C.V.Dang: Glutaminolysis: supplying carbon or nitrogen or both for cancer cells?. Cell Cycle 9, 3884–3886, 2010.
125. R.A.Gatenby and R.J.Gillies: Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol 39, 1358–1366, 2007.
126. U.E.Martinez-Outschoorn, R.M.Balliet, D.B.Rivadeneira, B.Chiavarina, S.Pavlides, et al.: Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: a new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle 9, 3256–3276, 2010.
127. P.P.Hsu and D.M.Sabatini: Cancer cell metabolism: warburg and beyond. Cell 134, 703–707, 2008.
128. R.G.Jones and C.B.Thompson: Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 23, 537–548, 2009.
129. Y.Zhao, H.Liu, Z.Liu, Y.Ding, S.P.Ledoux, et al.: Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res 71, 4585–4597, 2011.
130. J.B.Wang, J.W.Erickson, R.Fuji, S.Ramachandran, P.Gao, et al.: Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18, 207–219, 2010.
131. M.Jang, S.S.Kim, and J.Lee: Cancer cell metabolism: implications for therapeutic targets. Exp Mol Med 45, e45, 2013.
132. Y.Zhao, E.B.Butler, and M.Tan: Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 4, e532, 2013.
133. K.Hanhineva, R.Torronen, I.Bondia-Pons, J.Pekkinen, M.Kolehmainen, et al.: Impact of dietary polyphenols on carbohydrate metabolism. Int J Mol Sci 11, 1365–1402, 2010.
134. F.Alzaid, H.M.Cheung, V.R.Preedy, and P.A.Sharp: Regulation of glucose transporter expression in human intestinal Caco-2 cells following exposure to an anthocyanin-rich berry extract. PLoS One 8, e78932, 2013.
135. T.L.Farrell, S.L.Ellam, T.Forrelli, and G.Williamson: Attenuation of glucose transport across Caco-2 cell monolayers by a polyphenol-rich herbal extract: interactions with SGLT1 and GLUT2 transporters. Biofactors 39, 448–456, 2013.
136. G.Williamson: Possible effects of dietary polyphenols on sugar absorption and digestion. Mol Nutr Food Res 57, 48–57, 2013.
137. W.Zhang, Y.Liu, X.Chen, and S.C.Bergmeier: Novel inhibitors of basal glucose transport as potential anticancer agents. Bioorg Med Chem Lett 20, 2191–2194, 2010.
138. Y.J.Surh: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3, 768–780, 2003.
139. D.W.Li, P.Dong, F.Wang, X.W.Chen, C.Z.Xu, et al.: Hypoxia induced multidrug resistance of laryngeal cancer cells via hypoxia-inducible factor-1alpha. Asian Pac J Cancer Prev 14, 4853–4858, 2013.
140. R.Wang, S.Zhou, and S.Li: Cancer therapeutic agents targeting hypoxia-inducible factor-1. Curr Med Chem 18, 3168–3189, 2011.
141. S.Sun, S.Pan, A.Miao, C.Ling, S.Pang, et al.: Active extracts of black tea (Camellia Sinensis) induce apoptosis of PC-3 prostate cancer cells via mitochondrial dysfunction. Oncol Rep 30, 763–772, 2013.
142. M.Tasyriq, I.A.Najmuldeen, L.L.In, K.Mohamad, K.Awang, et al.: 7alpha-hydroxy-beta-sitosterol from chisocheton tomentosus induces apoptosis via dysregulation of cellular Bax/Bcl-2 ratio and cell cycle arrest by downregulating ERK1/2 activation. Evid Based Complement Alternat Med 2012, 765316, 2012.
143. M.Singh, R.Singh, K.Bhui, S.Tyagi, Z.Mahmood, et al.: Tea polyphenols induce apoptosis through mitochondrial pathway and by inhibiting nuclear factor-kappaB and Akt activation in human cervical cancer cells. Oncol Res 19, 245–257, 2011.
144. L.D.Guo, X.J.Chen, Y.H.Hu, Z.J.Yu, D.Wang, et al.: Curcumin inhibits proliferation and induces apoptosis of human colorectal cancer cells by activating the mitochondria apoptotic pathway. Phytother Res 27, 422–430, 2013.
145. Q.Y.Chen, G.H.Lu, Y.Q.Wu, Y.Zheng, K.Xu, et al.: Curcumin induces mitochondria pathway mediated cell apoptosis in A549 lung adenocarcinoma cells. Oncol Rep 23, 1285–1292, 2010.
146. K.D.Crew, K.A.Ho, P.Brown, H.Greenlee, T.B.Bevers, et al.: Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer. J Hum Nutr Diet 28(3), 272–282, 2014.
147. J.Chen, D.Zhuang, W.Cai, L.Xu, E.Li, et al.: Inhibitory effects of four plants flavonoids extracts on fatty acid synthase. J Environ Sci 21 Suppl 1, S131–S134, 2009.